C5orf66 | Chromosome 5 open reading frame 66 | | | | | | Tissue enhanced |
C9orf139 | Chromosome 9 open reading frame 139 | | | | | | Tissue enhanced |
CABP4 | Calcium binding protein 4 | Disease related genes
| | | | | Tissue enhanced |
CARD11 | Caspase recruitment domain family, member 11 | Cancer-related genes Disease related genes
| | | | | Tissue enhanced |
CARD9 | Caspase recruitment domain family, member 9 | Disease related genes
| | | | | Tissue enhanced |
CASS4 | Cas scaffolding protein family member 4 | Cytoskeleton related proteins Plasma proteins
| | | | | Tissue enhanced |
CBX4 | Chromobox homolog 4 | | | | | | Tissue enhanced |
CCL14 | Chemokine (C-C motif) ligand 14 | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CCL17 | Chemokine (C-C motif) ligand 17 | Predicted secreted proteins
| | | | | Tissue enhanced |
CCL19 | Chemokine (C-C motif) ligand 19 | Cancer-related genes Predicted secreted proteins
| | | | | Tissue enhanced |
CCL21 | Chemokine (C-C motif) ligand 21 | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CCL22 | Chemokine (C-C motif) ligand 22 | Predicted secreted proteins
| | | | | Tissue enhanced |
CCL3 | Chemokine (C-C motif) ligand 3 | Cancer-related genes Predicted secreted proteins
| | | | | Tissue enhanced |
CCL3L1 | Chemokine (C-C motif) ligand 3-like 1 | Predicted secreted proteins
| | | | | Tissue enhanced |
CCL3L3 | Chemokine (C-C motif) ligand 3-like 3 | Predicted secreted proteins
| | | | | Tissue enhanced |
CCL4 | Chemokine (C-C motif) ligand 4 | Cancer-related genes Predicted secreted proteins
| | | | | Tissue enhanced |
CCL4L1 | Chemokine (C-C motif) ligand 4-like 1 | Predicted secreted proteins
| | | | | Tissue enhanced |
CCL4L2 | Chemokine (C-C motif) ligand 4-like 2 | Predicted secreted proteins
| | | | | Tissue enhanced |
CCNE1 | Cyclin E1 | Cancer-related genes
| | | | | Tissue enhanced |
CCR2 | Chemokine (C-C motif) receptor 2 | CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CCR4 | Chemokine (C-C motif) receptor 4 | CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CCRN4L | CCR4 carbon catabolite repression 4-like (S. cerevisiae) | Enzymes
| | | | | Tissue enhanced |
CD160 | CD160 molecule | CD markers Predicted secreted proteins
| | | | | Tissue enhanced |
CD180 | CD180 molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD2 | CD2 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD22 | CD22 molecule | CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD226 | CD226 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD244 | CD244 molecule, natural killer cell receptor 2B4 | CD markers Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CD247 | CD247 molecule | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
CD27 | CD27 molecule | Cancer-related genes CD markers Disease related genes Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CD28 | CD28 molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD300E | CD300e molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD300LB | CD300 molecule-like family member b | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD300LF | CD300 molecule-like family member f | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD3D | CD3d molecule, delta (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD3E | CD3e molecule, epsilon (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
CD3G | CD3g molecule, gamma (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD40LG | CD40 ligand | Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
CD48 | CD48 molecule | CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD5 | CD5 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD6 | CD6 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD69 | CD69 molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD7 | CD7 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD79A | CD79a molecule, immunoglobulin-associated alpha | Cancer-related genes CD markers Disease related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD79B | CD79b molecule, immunoglobulin-associated beta | Cancer-related genes CD markers Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
CD80 | CD80 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD83 | CD83 molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD84 | CD84 molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD8A | CD8a molecule | CD markers Disease related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD8B | CD8b molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |